+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Pulmonary Arterial Hypertension (PAH) Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026

  • ID: 4701680
  • Report
  • September 2018
  • Region: Global
  • Acute Market Reports
1 of 3

FEATURED COMPANIES

  • Bayer AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck KGaA
  • Novartis International AG
  • Nuventra Pharma Sciences
  • MORE
Pulmonary Arterial Hypertension (PAH) Treatment Market Growth, Future Prospects, and Competitive Analysis, 2018–2026 the pulmonary arterial hypertension treatment market was valued at US$ 7,802.9 Mn in 2017 and projected to reach US$ 14,642.1 Mn by 2026 at a CAGR of 7.6% over the forecast period from 2018 to 2026.

Market Insights
The pulmonary arterial hypertension (PAH) treatment market is expected to exhibit a remarkable CAGR during the forecast period from 2018 to 2026. PAH is a rare, progressive disorder characterized by high blood pressure in the arteries that go from heart to the lungs. Drivers accountable for the market growth are globally growing older population coupled with mounting prevalence of PAH due to causative diseases including lung diseases, human immunodeficiency virus (HIV) infection, connective tissue disorders, chronic liver diseases, sedentary lifestyle, and other idiopathic conditions.

Moreover, increasing launches of innovative drugs & treatment therapies, favorable initiatives by various governments, and rising spending over healthcare is supporting the market growth. The European Respiratory Society (ERS) reported that the worldwide prevalence of PAH is ranging from 10 to 52 cases per million and estimated to be in the range of 100,000–200,000 every year. The presence of favorable government support in the U.S. such as Orphan Drug Act (ODA) 1983 and the Rare Disease Act (RDA) of 2002 to facilitate the development of orphan drugs with benefits including tax incentives (reduced taxes/tax credits equal to half of the development costs), clinical research subsidies, and improved patent protection & marketing rights. In addition, RDA amended to create a centralized structure (statutory authorization) for coordinating the research or recommend national research agendas in order to better facilitate the research & education.

The market dynamics would be varying by the end of 2020 as some of the blockbuster PAH treatment drugs such as Tracleer (bosentan), Adcirca, Letairis, and Tyvaso will go off-patent after 2018 and the entry of generic drugs with reduced prices than patented drugs would get facilitated.

Key Market Movements:
  • Globally, the pulmonary arterial hypertension treatment market to exhibit a lucrative growth with a CAGR of 7.6% during the forecast period from 2018 to 2026
  • Based on drug class, the vasodilators segment would register the fastest CAGR during the forecast period due to rising number of prescriptions & sale of prostacyclin and prostacyclin analogs such as Flolan (epoprostenol), Remodulin/Orenitram/Tyvaso (treprostinil), Ventavis (iloprost), Uptravi (selexipag), and Veletri (epoprostenol). These vasodilators will surpass the endothelin receptor antagonists (ERAs) in terms of revenue by the end of 2018 due to launch of blockbuster drugs like Uptravi and Ventavis in recent years, and launch of potential pipeline drugs in the near future.
  • The presence of key market participants, supportive government initiatives, and sophisticated healthcare infrastructure, and rising prevalence of risk factors for PAH in the U.S. and Canada would facilitate North America’s supremacy throughout the forecast period
  • Asia Pacific is envisaged to exhibit the fastest market growth over the forecast period and would retain its status quo owing to growing elderly population base coupled with increasing incidence of causative diseases of PAH, and rising spending on healthcare in China, India, Japan, and Australia
  • Major players in this vertical are GlaxoSmithKline plc; Pfizer Inc.; Gilead Sciences, Inc.; Novartis International AG; Bayer AG; Merck KGaA; Bristol-Myers Squibb Company; United Therapeutics Corporation; Actelion Pharmaceuticals Ltd; Reata Pharmaceuticals, Inc.; Toray Industries, Inc.; Liquidia Technologies, Inc.; and Nuventra Pharma Sciences
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Bayer AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck KGaA
  • Novartis International AG
  • Nuventra Pharma Sciences
  • MORE
Chapter 1 Preface
1.1 Report Scope and Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Approaches Adopted
1.3.4.1 Top-Down Approach
1.3.4.2 Bottom-Up Approach
1.3.5 Assumptions
1.4 Market Segmentation

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Pulmonary Arterial Hypertension Treatment Market
2.1.1 Global Pulmonary Arterial Hypertension Treatment Market, by Drug Class, 2017 (US$ Mn)
2.1.2 Global Pulmonary Arterial Hypertension Treatment Market, by Geography, 2017 (US$ Mn)

Chapter 3 Market Dynamics
3.1 Introduction
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 Globally Growing Elderly Population Coupled with Rising Prevalence of PAH
3.2.1.2 Driver
3.2.2 Challenges
3.2.2.1 Challenge
3.2.2.2 Challenge
3.2.3 Opportunities
3.2.3.1 Opportunity
3.2.3.2 Opportunity
3.3 Attractive Investment Proposition, by Geography, 2017
3.4 Market Positioning of Key Players, 2017

Chapter 4 Global Pulmonary Arterial Hypertension Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
4.1 Overview
4.2 Endothelin Receptor Antagonists (ERAs)
4.3 Vasodilators
4.4 Phosphodiesterase-5 (PDE-5) Inhibitors
4.5 Soluble Guanylate Cyclase (sGC) Stimulators
4.6 Calcium Channel Blockers (CCBs)
4.7 Others (anticoagulants, diuretics, and cardiac glycosides)
4.8 Pipeline Analysis
4.8.1 Phase III (Forecast till 2026) (US$ Mn)
4.8.1.1 Beraprost Sodium 314d Modified Release (BPS-314d-MR)
4.8.1.2 LIQ861 Inhaled Treprostinil
4.8.2 Phase II & I (Tabular Format)

Chapter 5 Global Pulmonary Arterial Hypertension Treatment Market, by Geography, 2016–2026 (US$ Mn)
5.1 Overview
5.2 North America
5.2.1 North America Pulmonary Arterial Hypertension Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
5.2.2 North America Pulmonary Arterial Hypertension Treatment Market, by Country, 2016–2026 (US$ Mn)
5.2.2.1 U.S.
5.2.2.2 Canada
5.3 Europe Pulmonary Arterial Hypertension Treatment Market, 2016–2026 (US$ Mn)
5.3.1 Europe Pulmonary Arterial Hypertension Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
5.3.2 Europe Pulmonary Arterial Hypertension Treatment Market, by Country/Region, 2016–2026 (US$ Mn)
5.3.2.1 U.K.
5.3.2.2 Germany
5.3.2.3 Rest of Europe
5.4 Asia Pacific Pulmonary Arterial Hypertension Treatment Market, 2016–2026 (US$ Mn)
5.4.1 Asia Pacific Pulmonary Arterial Hypertension Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
5.4.2 Asia Pacific Pulmonary Arterial Hypertension Treatment Market, by Country/Region, 2016–2026 (US$ Mn)
5.4.2.1 Japan
5.4.2.2 China
5.4.2.3 Rest of Asia Pacific
5.5 Latin America Pulmonary Arterial Hypertension Treatment Market, 2016–2026 (US$ Mn)
5.5.1 Latin America Pulmonary Arterial Hypertension Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
5.5.2 Latin America Pulmonary Arterial Hypertension Treatment Market, by Country/Region, 2016–2026 (US$ Mn)
5.5.2.1 Brazil
5.5.2.2 Mexico
5.5.2.3 Rest of Latin America
5.6 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market, 2016–2026 (US$ Mn)
5.6.1 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
5.6.2 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market, by Region, 2016–2026 (US$ Mn)
5.6.2.1 GCC
5.6.2.2 Rest of Middle East & Africa

Chapter 6 Company Profiles
6.1 GlaxoSmithKline plc
6.2 Pfizer Inc.
6.3 Gilead Sciences, Inc.
6.4 Novartis International AG
6.5 Bayer AG
6.6 Merck KGaA
6.7 Bristol-Myers Squibb Company
6.8 United Therapeutics Corporation
6.9 Actelion Pharmaceuticals Ltd
6.10 Reata Pharmaceuticals, Inc.
6.11 Toray Industries, Inc.
6.12 Liquidia Technologies, Inc.
6.13 Nuventra Pharma Sciences

List of Figures
FIG. 1 Global Pulmonary Arterial Hypertension Treatment Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Pulmonary Arterial Hypertension Treatment Market Segmentation
FIG. 4 Global Pulmonary Arterial Hypertension Treatment Market, by Drug Class, 2017 (US$ Mn)
FIG. 5 Global Pulmonary Arterial Hypertension Treatment Market, by Geography, 2017 (US$ Mn)
FIG. 6 Attractive Investment Proposition, by Geography, 2017
FIG. 7 Global Market Positioning of Key Pulmonary Arterial Hypertension Treatment Manufacturers, 2017
FIG. 8 Global Endothelin Receptor Antagonists (ERAs) Market for Pulmonary Arterial Hypertension Treatment, 2016–2026 (US$ Mn)
FIG. 9 Global Vasodilators Market for Pulmonary Arterial Hypertension Treatment, 2016–2026 (US$ Mn)
FIG. 10 Global Phosphodiesterase-5 (PDE-5) Inhibitors Market for Pulmonary Arterial Hypertension Treatment, 2016–2026 (US$ Mn)
FIG. 11 Global Soluble Guanylate Cyclase (sGC) Stimulators Market for Pulmonary Arterial Hypertension Treatment, 2016–2026 (US$ Mn)
FIG. 12 Global Calcium Channel Blockers (CCBs) Market for Pulmonary Arterial Hypertension Treatment, 2016–2026 (US$ Mn)
FIG. 13 Global Others Market for Pulmonary Arterial Hypertension Treatment, 2016–2026 (US$ Mn)
FIG. 14 U.S. Pulmonary Arterial Hypertension Treatment Market, 2016–2026 (US$ Mn)
FIG. 15 Canada Pulmonary Arterial Hypertension Treatment Market, 2016–2026 (US$ Mn)
FIG. 16 U.K. Pulmonary Arterial Hypertension Treatment Market, 2016–2026 (US$ Mn)
FIG. 17 Germany Pulmonary Arterial Hypertension Treatment Market, 2016–2026 (US$ Mn)
FIG. 18 Rest of Europe Pulmonary Arterial Hypertension Treatment Market, 2016–2026 (US$ Mn)
FIG. 19 Japan Pulmonary Arterial Hypertension Treatment Market, 2016–2026 (US$ Mn)
FIG. 20 China Pulmonary Arterial Hypertension Treatment Market, 2016–2026 (US$ Mn)
FIG. 21 Rest of Asia Pacific Pulmonary Arterial Hypertension Treatment Market, 2016–2026 (US$ Mn)
FIG. 22 Brazil Pulmonary Arterial Hypertension Treatment Market, 2016–2026 (US$ Mn)
FIG. 23 Mexico Pulmonary Arterial Hypertension Treatment Market, 2016–2026 (US$ Mn)
FIG. 24 Rest of Latin America Pulmonary Arterial Hypertension Treatment Market, 2016–2026 (US$ Mn)
FIG. 25 GCC Pulmonary Arterial Hypertension Treatment Market, 2016–2026 (US$ Mn)
FIG. 26 Rest of Middle East & Africa Pulmonary Arterial Hypertension Treatment Market, 2016–2026 (US$ Mn)

List of Tables
TABLE 1 Market Snapshot: Global Pulmonary Arterial Hypertension Treatment Market (US$ Mn)
TABLE 2 Global Pulmonary Arterial Hypertension Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 3 Pulmonary Arterial Hypertension Treatment Drugs’ Pipeline Analysis
TABLE 4 Global Pulmonary Arterial Hypertension Treatment Market, by Geography, 2016–2026 (US$ Mn)
TABLE 5 North America Pulmonary Arterial Hypertension Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 6 North America Pulmonary Arterial Hypertension Treatment Market, by Country, 2016–2026 (US$ Mn)
TABLE 7 Europe Pulmonary Arterial Hypertension Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 8 Europe Pulmonary Arterial Hypertension Treatment Market, by Country/Region, 2016–2026 (US$ Mn)
TABLE 9 Latin America Pulmonary Arterial Hypertension Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 10 Latin America Pulmonary Arterial Hypertension Treatment Market, by Country/Region, 2016–2026 (US$ Mn)
TABLE 11 Asia Pacific Pulmonary Arterial Hypertension Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 12 Asia Pacific Pulmonary Arterial Hypertension Treatment Market, by Country/Region, 2016–2026 (US$ Mn)
TABLE 13 Latin America Pulmonary Arterial Hypertension Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 14 Latin America Pulmonary Arterial Hypertension Treatment Market, by Country/Region, 2016–2026 (US$ Mn)
TABLE 15 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market, by Drug Class, 2016–2026 (US$ Mn)
TABLE 16 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market, by Region, 2016–2026 (US$ Mn)
TABLE 17 GlaxoSmithKline plc: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Business Description/Key Developments)
TABLE 18 Pfizer Inc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Business Description/Key Developments)
TABLE 19 Gilead Sciences, Inc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Business Overview/Key Developments)
TABLE 20 Novartis International AG: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Business Description/Key Developments)
TABLE 21 Bayer AG: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Business Description/Key Developments)
TABLE 22 Merck KGaA: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Business Description/Key Developments)
TABLE 23 Bristol-Myers Squibb Company: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Business Description/Key Developments)
TABLE 24 United Therapeutics Corporation: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Business Description/Key Developments)
TABLE 25 Actelion Pharmaceuticals Ltd: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Business Description/Key Developments)
TABLE 26 Reata Pharmaceuticals, Inc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Business Description/Key Developments)
TABLE 27 Toray Industries, Inc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Business Description/Key Developments)
TABLE 28 Liquidia Technologies, Inc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Business Description/Key Developments)
TABLE 29 Nuventra Pharma Sciences: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Business Description/Key Developments)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Gilead Sciences, Inc.
  • Novartis International AG
  • Bayer AG
  • Merck KGaA
  • Bristol-Myers Squibb Company
  • United Therapeutics Corporation
  • Actelion Pharmaceuticals Ltd
  • Reata Pharmaceuticals, Inc.
  • Toray Industries, Inc.
  • Liquidia Technologies, Inc.
  • Nuventra Pharma Sciences
Note: Product cover images may vary from those shown
Adroll
adroll